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Abstract
Although CD4+ T cells are generally accepted to be responsible for the determination of
resistance to infection in experimental murlne cutaneous lelshmanlasls, a contribution of CD8+
lymphocytes to Immunity can be demonstrated under certain well-defined conditions. Normally
highly susceptible BALB/c mice can be rendered resistant to Infection with Leishmania major
promastigotes by a single Injection of monoclonal anti-CD4 antibodies at the beginning of
Infection. Mice treated In such a way can heal their primary cutaneous lesions and acquire
immunity to subsequent challenge Infection. Both the resolution of the primary Infection and the
Induced state of Immunity to reinfection In these mice Is shown to be dependent upon the anti-
lelshmanlal effector functions of CD8+ T cells. Furthermore, In contrast to control Infected
BALB/c mice, which are unable to mount a delayed-type hypersensltivity (DTH) response to
viable parasites, mice cured as a result of treatment with antl-CD4 antibodies In vivo exhibit a
strong DTH response, which can be significantly reduced by Injection of either antl-CD4 or antl-
CD8 monoclonal antibodies prior to antigenlc challenge with viable promastigotes. Moreover,
Increased numbers of specific CD8+ T cells, able to transfer Le/shman/a-speclflc DTH responses,
were found In lymphold organs of BALB/c mice rendered resistant to Infection by
Immunolnterventlon with anti-CD4 monoclonal antibodies at the beginning of infection.
Neutralization In vivo of Interleukln 4 during the course of infection In BALB/c mice also enables
these otherwise susceptible mice to resolve their cutaneous lesions and to decrease the parasite
burden In Infected tissues. CD8+ T cells are required for both of these beneficial effects. Taken
together, these results indicate that In the immune BALB/c mouse, as in the normally resistant
CBA mouse, CD8+ lymphocytes are Involved In the elimination of L. major and in the
establishment and maintenance of Immunity against infection with this parasite.
Introduction
Leishmania major, one of the causative agents of cutaneous
leishmaniasis in man, is a protozoan parasite that infects
mononuclear phagocytes in its vertebrate hosts. The various
clinical manifestations of human leishmaniasis can be mimicked
in mice from various inbred strains upon infection with L. major.
The majority of inbred strains of mice are relatively resistant to
infection with this parasite in that they develop only small lesions
at the site of inoculation, which spontaneously resolve within a
few weeks. In contrast, mice from a few strains, such as BALB/c,
develop severe lesions at the site of parasite inoculation. These
lesions show no tendency to resolve, and eventually fatal
visceralization of the infection occurs (1,2).
The importance of CD4+ T cells in resolution of cutaneous
lesions induced by L. major in mice is firmly established (3 - 5).
However, results are accumulating which indicate that CD8+ T
cells also participate in the resolution of L ma/or-induced lesions.
A role for CD8+ T cells in immunity to infection with this parasite
was first suggested by observations showing the activation of
larger numbers of parasite-specific CD8+ T cells in resistant
than in susceptible mice during the course of a primary infec-
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tion (6). Secondly, administration of anti-CD8 monoclonal
antibodies was shown to enhance significantly the development
of lesions in resistant mice, even though this treatment did not
modify the outcome of infection (7). Thirdly, it has recently been
shown that adult thymectomized BALB/c mice treated with ct-CD4
mAb, which are thus virtually free of CD4 + T cells, are able to
control infection induced by L. major amastigotes through the
activity of CD8+ T cells mediating specific delayed-type
hypersensitivity (DTH) reactions (8). Fourthly, resistance to infec-
tion, acquired by intravenous immunization of susceptible mice
with killed promastigotes, was prevented by depletion of CD8+
T cells in vivo (9). Finally, recent results from our laboratory have
shown that in resistant mice CD8+ T cells also appear to be
important in controlling the lesions developing upon infectious
challenge of immune mice, which had spontaneously cured their
primary infections (10).
In the murine model of generalized visceral infection with
Leishmania donovani, results show that the majority of specific
T cells in the liver of resistant B10 mice, at the time when parasite
load begins to decrease rapidly, express the CD8+ surface
phenotype (11). Furthermore, CD8+ T cells have been
demonstrated to contribute to immunity to reinfection of mice with
L. donovani (12).
Several studies have demonstrated that susceptibility of normal
BALB/c mice to infection with L. major can be overcome by
various immunological interventions. For example, administra-
tion of a-CD4 mAb to normal BALB/c mice at the beginning of
infection enables them to resolve their primary infection and
render them resistant to reinfection (13-16). Treatment of
BALB/c mice with a-interieukin 4 (IL-4) mAb has also been shown
to reverse their extreme susceptibility to infection (17). In the
present study, we show that the state of resistance to infection
seen in BALB/c mice as a result of either of these two interven-
tions on the immune system depends upon the triggering and
the activity of CD8+ T cells.
Methods
Mice
Adult BALB/c mice were either obtained from the animal colony
maintained at the Institut Pasteur Pans or purchased from IFFA-
Credo, Saint-Germain-sur-l'Arbresle, France.
Parasites
L. major LV39 (MRHO/SU/59/P-strain) was kept virulent by
continuous passage into mice. Parasites isolated from skin lesions
of infected mice were grown at 26°C in Dulbecco's modified
Eagle's medium (DMEM) on a solid layer of rabbit blood-agar
as previously described (18).
Infection of mice and monitoring of lesions
Mice were infected s.c. in one hind footpad with 2x 106 L. major
promastigotes, obtained from cultures in the stationary growth
phase, in a final volume of 50 /d. The development of lesions was
monitored weekly by measuring the increase of footpad thickness
compared to the uninfected contralateral footpad.
Determination of the number of viable L. major parasites in
infected mouse tissues
Viable L. major parasites in infected tissues were enumerated
using a limiting dilution assay described elsewhere (19). Briefly,
dilutions of infected tissue homogenates were placed in the wells
of micrcititer plates which contained rabbit blood-agar slants. After
10-12 days incubation at 26°C, the wells containing growing
parasites were identified by microscopic examination. Estima-
tion of the frequency of L. major recovered from a given tissue
was determined by minimum x2 analysis applied to Poisson
distribution.
Delayed-type hypersensitivity (DTH)
DTH responses were elicited by s.c. injection of either 2X106
infective L. major promastigotes or frozen-and-thawed lysates of
L. major promastigotes (L.m.Ag) in a final volume of 50 /il into
one hind footpad. The doses of L.m.Ag employed are expressed
in terms of the numbers of promastigotes used to prepare the
antigen. The DTH reaction was quantitated by measuring at
various times (6, 12, 24, and 48 h) the increase in footpad
thickness, i.e. the difference between the thickness of the injected
footpad and the control footpad by using a dial-gauge caliper
(precision 0.05 mm. Kroplm, Schluchtern, FRG).
Estimation of the frequency of L. major specific T cells capable
of mediating specific DTH reaction
The adoptive transfer of DTH reaction was performed by inject-
ing cells from sensitized animals together with viable L. major
promastigotes as antigen into one hind footpad of normal
syngeneic mice. The limiting dilution analysis to determine the
frequency of DTH-mediating T cells in lymphoid tissues has been
described (20,21). In brief, three serial dilutions of lymphoid cells
were mixed with viable L. major promastigotes, and 50 /A of cell
suspensions were injected into one hind footpad of normal
syngeneic mice (10-12 recipients for each dilution). The DTH
reaction was quantitated by measuring the increase in footpad
thickness 18 h later. Since.the DTH-mediating activity is reflected
by an increase in footpad thickness, the frequency determina-
tion of DTH-mediating T cells by limiting dilution assay implies
the definition of values in which the swelling footpad response
is scored as negative (negative transfer). The upper value of
footpad thickness increase related to negative transfer was
calculated from the mean (m) value of increase of footpad
thickness measured after local injection of diluted suspensions
of unsensitized cells (or sensitized cells against an unrelated
antigen) mixed with 2 x 106 L. major promastigotes, into 10-12
naive recipients. To this value (m) was added the product
SDxf005 m which SD represents the standard deviation and f
is the value of Student's 'for P = 0.05. The experimental values
were always inferior to such a calculated value (0.20 mm) when
cell suspensions and antigen were prepared under the
appropriate conditions and mice were kept on a clean litter. The
frequency of specific T cells was calculated as described (6).
mAbs
Rat mAb GK 1.5 (lgG2b, a-CD4) (22) and a-CD8 mAb 31M (IgM)
(23) were kindly provided by Dr F. W. Fitch, University of Chicago,
Chicago, IL. Rat mAb H35.17.2 (lgG2b, a-CD8) (24) was kindly
supplied by Dr M. Pierres, INSERM/CNRS, Marseille, France.
Rat mAb 11B11 (lgG1, a-murine-IL-4) (25) was a gift of Dr W.
Paul, National Institutes of Health, Bethesda, Maryland, USA and
rat mAb AN-18.17.24 (a-murine interferon (IFN-7) was a gift of
Dr S. Landolfo, University of Torino, Torino, Italy (26). Rat mAb
R4-6A2 (IgGi, a-murine IFN-Y) (27) was obtained by Dr G.
Spitalny. Rat mAb RL 172.4 (IgM, a-CD4) (28) was a gift of Dr
H. R. MacDonald, Ludwig Institute for Cancer Research,
Epalinges, Switzerland. a-DNP mAb LO-DNP-11 (rat, IgG 2b)
was kindly provided by Dr H. Bazin, Brussels, Belgium (29).
Treatment with mAb in vivo
Unless otherwise stated, semi-purified mAb (ammonium sulphate
precipitation) from ascites fluid were injected i.p. or i.v. in
phosphate-buffered saline at the indicated doses.
Preparation of T cell subset-depleted cell suspensions from
lymphoid tissues
Before transfer, single-cell suspensions (5x107 nucleated
cells/ml) were incubated with a 1/10 dilution of hybndoma culture
supernatant containing mAb (lgM) directed against either the CD4
or CD8 T cell surface antigen and a 1/40 dilution of guinea pig
serum as a source of complement. The T cell subset-depleted
suspensions were washed twice before use in adoptive transfer
experiments.
Two-color fluorescence staining and fluorescence-activated cell
sorter (FACS) analysis
Samples of 2x10® cells were stained with a mixture of
phycoerythrin-labeled a-CD4 mAb (GK 1.5, Becton Dickinson,
Mountain View, CA) and 5-(4,6-dichlorotnazinyf) aminofluorescein-
conjugated a-CD8 mAb (H35.17.2). Samples were analyzed on
a flow microfluorometer (FACS II, Becton Dickinson, Mountain
View, CA) gated by a combination of narrow-angle forward light
scatter and perpendicular light scatter to exclude nonviable cells
(30).
Lymphocyte cultures
Spleen cells (4x106/ml) were stimulated in the presence or
absence of 1 x106/ml live L. major promastigotes, inactivated
by 2-5-min irradiation with UV light or L.m.Ag. at 37°C, 7%
CO2 in 24-well Costar plates in a final volume of 2 ml. DMEM
(Seromed, Berlin, FRG) supplemented with 5% heat-inactivated
FCS (Seromed), L-asparagine (36 mg/1), L-glutamine (216 mg/l),
L-arginine (200 mg/l), 5x10~5 M 2-mercaptoethanol, 10 mM
HEPES, 100U/ml penicillin and 100^g/ml streptomycin was
used as culture medium. Twenty-four hours later, supernatants
(SN) were removed and stored in small aliquots at -20°C until
use to measure their content in various lymphokines.
Detection of IL-2, IFN-y, and tumor necrosis factor (TNF) in SN
IL-2 activities were determined by measuring the lysosomal
enzyme A/-acetyl-0-D-hexosaminidase of an IL-2-dependent
murme cytotoxic T cell line (CTLL) as described (31). The CTLL
were kindly provided by Dr R. MacDonald, Ludwig Institute for
Cancer Research, Epalinges, Switzerland. CTLL (4000 cells per
well) were incubated with serially diluted (log2 dilutions) test
samples in 96-well flat bottom plates (Costar). Recombinant
mouse IL-2 was used as a positive control. Recombinant mouse
IL-2 expressed in X63Ag8-653 ptasmacytoma cells was a gift from
Dr F. Metehers, Base) Institute for Immunology, Basel, Switzerland
(32). After 48 h incubation at 37°C, 7% CO2 the plates were
centrifuged, the supernatants removed, the cells washed twice
with PBS, and incubated with 60 /J of substrate. The chromogenic
substrate for the hexosaminidase, p-nitro-phenyl-A/-acetyl-/3-r>
glucosaminide was dissolved at 7.5 mM in 0.1 M citrate buffer,
pH 5. The substrate solution was mixed with an equal volume
of 0.5% Triton X-100 in water and added to the CTLL. After
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16-20 h incubation at 37°C, 7% CO2, the color reaction was
developed and enzyme activity stopped by addition of 90 jd per
well of 50 mM glycine buffer, pH 10.4, containing 5 mM ETDA.
The absorbance was measured at 405 nm 10 min later.
IFN-7 activity was measured by ELISA as described (33).
ELISA microtiter plates (96-well) (Dynatech, Alexandria, VA) were
coated with 5 /xg/ml of protein G-purified rat anti-mouse IFN-7
mAb R4-6A2, in PBS, pH 7.2. Free binding sites were blocked
with 1 % (w/v) BSA (Fluka, Buchs, Switzerland) for 2 h at 37°C.
Plates were then washed three times with ELISA washing buffer.
Different 2-fold dilutions (in PBS, 1 % BSA) of the test samples
were added to the plates, and incubated overnight at 4°C in a
moist chamber. A standard curve was constructed by assaying
serial dilutions of mouse r-IFN-7 at starting concentrations of 1600
U/ml in PBS, 1 % BSA. After three washes, biotin-labeled protein
G-purified rat anti-mouse IFN-7 mAb AN-18.17.24 at 1 /xg/ml in
PBS, 1 % BSA, was added to each well and incubated for 2 h
at 37°C. After three more washes, wells were incubated for 1 h
at 37°C with horseradish peroxidase-conjugated biotin-strepta-
vidin (BRL, Gaithersburg, MD) diluted in PBS. The enzymatic
reaction was developed with o-phenylenediamine (BRL) as
chromogen (1 mg/ml in 0.1 M sodium citrate buffer, pH 4.5, and
0.012% HgOJ for 10-15 min in the dark. The reaction was
then stopped by addition of an equal volume of 2 M HjSO,,.
Absorbance was measured at 492 nm.
Cells of the fibrosarcoma line WEHI 164, clone 13 (34), a gift
of Dr Espevik, University of Trondheim, Trondheim, Norway, were
used for the detection of biologically active TNF. Duplicate
samples were tested for cytotoxic activity by incubating serial dilu-
tions with exiO^ml WEHI 164 clone 13 cells and 0.5 mg/ml
actinomycin D (Sigma, St Louis, MO) in a final volume of 0.2 ml
in flat-bottom microtiter plates. After 24 h of incubation,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide
(MTT, Sigma) was added (50 y\ of MTT solution of 5 mg/ml in
PBS) and incubated for 3 h at 37°C in a moist chamber. Plates
were then centnfuged, supernatants removed, and 100 /d of 0.04
N HCI in isopropanol were added to each well. Plates were
agitated for 5 min to dissolve the blue crystals, and absorbance
was measured with a multi-scan ELISA spectrophotometer, using
a 550 nm filter (35). A standard titration of recombinant murine
TNF-a (r-TNF-a, kindly provided by Dr G. R. Adolf, Ernst-
Boehringer-lnstitute, Vienna, Austria) at dilutions ranging from
653.3 pg/ml to 0.3 pg/ml was set up with each assay. Compared
to the standard curve, the activity of each sample was expressed
in pg/ml TNF. The detection threshold of the colorimetric assay
for TNF activity was 0.9 pg/ml.
Results
Effect of administration of a-CD4 mAb on cutaneous leishmaniasis
in BALB/c mice
The administration of a-CD4 mAb to BALB/c mice has been
shown by several investigators to reverse the extreme suscep-
tibility of these mice to infection with L. major (13 -15,36). Results
in Fig. 1 confirm this observation and further demonstrate that
this effect does not depend upon the continuous administration
of the or-CD4 mAb during infection. Mice given 600 HQ of aCD4
mAb over a 24-h period at the beginning of infection (10 days
before or after infectious challenge) were capable of resolving
their lesions around 60 days after infection. Interestingly, the
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Fig. 1 . Lesion development in BALB/c mice after treatment with a-CD4
mAb. Groups of susceptible BALB/c mice (10 mice per group) were
infected s.c. in one hind footpad with 2X106 virulent L. major
promastigotes. At the indicated times before or after infection, the animals
received two injections of 300 jig a-CD4 mAb i.p. Lesion size was deter-
mined by subtracting the footpad thickness of the non-infected footpads
from the infected ones
administration of a-CD4 mAb at later times (20 days after infec-
tion) did not result in a beneficial effect on the course of disease
(data not shown). Although the administration of mAb resulted
in the elimination of more than 95% of CD4+ T cells 2 days
later, 60 days after infection the percentage and the absolute
number of CD4+ T cells in lymph nodes of cured mice was very
similar to that seen in lymphoid tissues of normal BALB/c mice
(data not shown). The challenge of BALB/c mice, cured as a result
of administration of 600 /*g a-CD4 mAb at the beginning of a
primary infection led to the development of small lesions that
resolved spontaneously within 5 weeks, indicating that these mice
are immune to reinfection (Fig. 2).
CD8+ T cells play a role in the control of cutaneous
leishmaniasis in BALB/c mice rendered resistant by the
administration a-CD4 mAb at the beginning infection
Since previous results from this laboratory have shown that
CD8+ T cells contribute to the resistance to infection in immune
mice (9,10) it was of interest to determine whether or not CD8+
T cells also contribute to the ability of susceptible mice to resolve
their primary lesions as a result of administration of 600 /tg of
a-CD4 mAb at the beginning of infection. BALB/c mice were
infected s.c. in one hind footpad with 2x10* stationary phase
L. major promastigotes and separated into four groups. One
group was left untreated as a control. Mice from the second group
received 600 /ig of a-CD4 mAb GK 1.5 24 h after infection. Mice
from the third group also received 600 HQ of a-CD4 mAb 24 h
after infection and weekly injections of 150 fig a-CD8 mAb H35,
initiated 8 days after infection. Mice from the fourth group received
only weekly injections of 150/ig or-CD8 mAb. The disease
progression was monitored not only by measuring the size of
cutaneous lesions but also by determination of the numbers of
viable parasites in the lesions by limiting dilution analysis (19).
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Fig. 2. Course of infection in cured BALB/c mice. Susceptible BALB/c
mice, cured as a result of two injections of 300 ^g a-CD4 mAb at day
- 1 1 and day -10 before infection, were reinfected 60 days later with
2x10* virulent L. major promastigotes in the footpad opposite to the site
of primary infection. The development of lesions was determined by
subtracting the footpad thickness of the healed footpads from the
reinfected ones. Primary infected BALB/c mice were used as controls
(n - 7).
Compared to control infected mice, both the time course of
lesion development (data not shown) and the parasite numbers
in the lesions of mice treated only with a-CD8 mAb once per week
were not significantly different (for example, 9.25 x107
parasites/lesion in control infected mice and 6.7 x107
parasites/lesion in <*-CD8 treated BALB/c mice on day 47 after
infection). Thus, under the present experimental conditions, a
protective effect of CD8+ T cells could not be revealed during
the course of a primary infection in susceptible mice.
Results shown in Fig. 3 indicate that mice treated once with
a-CD4 mAb at the beginning of infection and also administered
a-CD8 mAb during the course of infection developed larger
lesions than mice treated only with a-CD4 mAb at the beginning
of infection. Moreover, compared to mice treated only once with
a-CD4 mAb, the numbers of viable parasites in lesions of mice
also given a-CD8 mAb were significantly higher as determined
on day 88 after infection. It is important to stress that the
therapeutic effect of a single injection of 600 HQ a-CD4 mAb could
not be completely reversed by weekly administration of the a-
CD8 mAb, since the lesions of those mice never reached the
size of the lesions of control infected mice, which lost their
footpads around 55 days after infection. The degree of deple-
tion of CD8+ T cells from lymphoid tissues after the administra-
tion of 0-CD8 mAb following the regimen described above was
documented by FACS analysis. For example, at day 88 the
absolute number of CD8+ T cells in the spleens of mice
administered a-CD8 mAb was reduced by 90% compared to
mice receiving only a-CD4 mAb at the beginning of infection.
More importantly, when enumerating the viable parasites by the
quantitative limiting dilution analysis, the lesions of mice given
a single injection of a-CD4 mAb and weekly injections of a-CD8
mAb contained about a million times more parasites than the
lesions of mice treated with only a single dose of a-CD4 mAb.
These data indicate that resistance to infection, which is seen
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Fig. 3. Contribution of CD8+ T cells to the reduction of lesion-size and parasite load in susceptible BALB/c mice, rendered resistant by injection
of a-CD4 mAb at the beginning of infection. BALB/c mice (4 groups of 6 mice) were infected s.c. in one hind footpad with 2 x 106 virulent L. ma/or
promastigotes. One day later, mice from two groups received a single injection of 600 /ig a-CD4 mAb i.p. In one of the groups treated with a single
injection of 600 /ig a-CD4 mAb as well as in one control infected group, CD8+ T cells were depleted by weekly injections, initiated 8 days after
infection, of 150 /ig a-CD8 mAb throughout the entire course of the experiment. Lesion size was determined by subtracting the footpad thickness
of the non-infected footpads from the infected ones. Parasite limiting dilution analysis was performed 88 days after infection. The control infected
BALB/c mice and the infected mice which were treated only with or-CD8 mAb once per week lost their footpads around day 55 after infection and
therefore the parasite burden in the lesions of these two groups was only determined on day 47 after infection. On that day, the size of lesions in
these two groups of mice was > 4 mm.
in susceptible mice treated with a-CD4 mAb at the beginning
of infection, depends—at least partly—upon the activity of CD8+
T cells.
Furthermore, the immunity to reinfection which is seen in
BALB/c mice rendered resistant by the injection of 600 ^g of
a-CD4 mAb at the beginning of a primary infection was found
to depend mainly upon the CD8+ T cell activity expressed early
during reinfection. Indeed, a single i.v. injection of 100 ng of a
a-CD8 mAb at the time of infectious challenge of cured BALB/c
mice led to the development of severe lesions. In contrast, a
similar treatment with a-CD4 mAb did not hamper the resolution
of secondary lesions (Fig. 4).
Contribution of CD8+ T cells to lymphokine production by
spleen cells of BALB/c mice rendered resistant by a single
injection of a-CD4 mAb
It appears that the effect of T cells on the course of cutaneous
leishmaniasis depends upon the activity of the lymphokines they
secrete (16,17,37). Therefore, the production of several
lymphokines was measured in the supernatants of specifically-
activated spleen cells from mice of the different groups described
above, at times when the lesions of a-CD4 mAb-treated mice
were resolved. Results in Fig. 5 show that compared to control
infected mice, the spleen cells from mice cured as a result of
treatment with a single dose of a-CD4 mAb at the beginning of
infection produced significantly higher amounts of IFN-7 in
response to stimulation with live promastigotes or L.m.Ag when
tested 88 days after infection. This difference in lymphokine
production is not due to a different composition of the spleen
cells put into culture, since the percentage of CD4+ and CD8+
T cells in the spleens of cured mice was restored to normal values.
The spleens of mice cured by a single injection of a-CD4 mAb
at the beginning of infection contained 16.5% CD4+ T cells and
6.3% CD8+ T cells and the spleens of control infected mice
contained 11.7% CD4+ and 5.7% CD8+ T cells. Similar results
were observed with IL-2 and TNF. In contrast, lymphokine
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Fig. 4. CD8+ T cells contribute to immunity to reinfection in BALB/c
mice, rendered resistant by the injection of 600 HQ or-CD4 mAb at the
beginning of infection. BALB/c mice were infected s.c. in one hind footpad
with 2x 106 virulent L. major promastigotes. At days 10 and 11 after
infection the animals received two injections of 300 HQ a-CD4 mAb i.p.
After the primary lesions were healed, mice were divided into four groups
(n = 6 mice per group) and injected i.v. with 100 /»g of either a-DNP,
a-CD4 or a-CD8 or a combination of a-CD4 and 0-CD8 mAb. 6 h later,
all mice were reinfected with 2x10® virulent L major promastigotes in
the footpad opposite to the site of primary infection. The course of
reinfection was monitored by measuring the lesion development.
production by spleen cells of mice given 600 ^g of a-CD4 mAb
at the beginning of infection and in addition treated weekly with
a-CD8 mAb was reduced to values below those seen in control
infected mice. Compared to mice cured as a result of a single
injection of a-CD4 mAb at the beginning of infection, the addi-
tional treatment with a-CD8 mAb resulted in a 75% reduction
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of CD8+ T cells and in a 70% increase of CD4+ T cells in the
spleen.
We observed that stimulation of immune spleen cells with live
promastigotes as a source of antigen resulted in the release of
higher amounts of lymphokines than stimulation with L.m.Ag. It
is noteworthy that, using a very sensitive immuno-assay for the
detection of IFN-7, it was possible to detect significant amounts
of IFN-y in supernatants from spleen cells from infected BALB/c
mice upon specific restimulation with live promastigotes in vitro
(Fig. 5).
In none of the supernatants taken 24 h after stimulation of
freshly isolated lymphoid cells could measurable amounts of IL-5
or IL-4 be detected.
DTH responses in BALB/c mice rendered resistant by the
injection of a-CD4 mAb at the beginning of infection: analysis
of the role of CD4 + and CD8+ T cells
The results described above indicate that the CD8+ T cell
subset is involved in the state of resistance resulting from one
injection of a-CD4 mAb in BALB/c mice. Therefore, experiments
were devised to detect the actual triggering of Leishmania-spedftc
CD8+ T cells directly in vivo by virtue of their ability to initiate
a DTH reaction at the site of injection of viable promastigotes.
After complete healing of the primary lesions (3 months after infec-
tion), mice were divided into three groups. The first group
received an i.v injection of 100 HQ a-DNP mAb, the second
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Fig. 5. Contribution of CD8 + T cells to lymphokine production by spleen
cells from BALB/c mice rendered resistant by a single injection of or-CD4
mAb. Spleen cells (4x lOfyml) of either control infected BALB/c mice,
or BALB/c mice cured as a result of injection of 600 pg a-CDA mAb 1
day after infection, or of mice injected 1 day after infection with 600 ^g
O-CD4 mAb and depleted of CD8+ T cells by weekly injections of 150 ^g
a-CD8 mAb, were stimulated in vitro with Ixir j fyml live L. major
pfomastigotes or 1 x lO^/ml L.m.Ag. on day 88 after infection. 24 h later,
supernatants were removed and tested for IFN-7, IL-2, and TNF.
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Fig. 6. Analysis of the role of CD4+ and CD8+ T cell in the develop-
ment of DTH responses in BALB/c mice, cured as a result of injection
of a-CD4 mAb at the beginning of infection. BALB/c mice were infected
with 2 x 106 virulent L. major promastigotes in one hind footpad (A) At
days 10 and 11 after infection, mice received two injections of 300 nQ
a-CD4 mAb i.p. After the primary lesions were healed (3 months after
infection), mice were divided into three groups and injected i.v. with 100 /tg
of either a-DNP, a-CD4 or a-CD8 mAb. 6 h later, mice were challenged
with 2x 106 virulent L. major promastigotes in the footpad opposite to
the site of primary infection and the DTH response was monitored by
measuring the footpad thickness at different times after challenge. (B)
Control infected BALB/c mice were treated in the same way as mice of
group A, except that they were not injected with a-CD4 mAb at days
10 and 11.
CD8+ T cells in L. major infections 593
group received 100 ^g of a-CD4 mAb i.v., and the third group
100 ;xg of a-CD8 mAb i.v. After 6 h, all mice were challenged
in the footpad opposite to the site of the primary infection with
2x 108 viable L. major promastigotes and the DTH response
was assessed by measuring the increase in footpad thickness
6,12, 24, and 48 h later. Results in Fig. 6 show that in contrast
to control infected mice (panel B), mice cured as a result of
immune intervention with or-CD4 mAb exhibited a strong DTH
response (panel A). This delayed inflammatory reaction was
100 iig aCD8 I.v.
100 ng aCD4 I.v.
100 H9 aONP I.v.
0 50 100 150 200 250
INCREASE IN FOOTPAD THICKNESS (1/100mm)
Fig. 7. Elicrtatjon of DTH responses in cured BALB/c mice with viable
L. major promastigotes or with soluble parasite lysates. After complete
healing of the primary lesions (3 months after infection), induced by two
injections of 300 /ig a-CD4 mAb at days 10 and 11 after s.c. infection
with 2 x 106 virulent L. major promastigotes, mice were divided into six
groups and injected i.v. with 100 ^g of either a-DNP, a-CD4 or a-CD8
mAb. 6 h later, DTH responses were induced by the injection of either
2x10° L.m.AG or 2 x108 virulent/., major promastigotes in the footpad
opposite to the site of primary infection. The DTH responses were
determined by subtracting the size of the footpad before challenge from
the footpad thickness after antigenic challenge.
abolished in mice given antj-CD4 mAb i.v. 6 h prior to challenge
with viable promastigotes. Although an inflammatory response
was still detectable in mice administered anfj-CD8 mAb 6 h before
antigenic challenge, the magnitude of the DTH response was
significantly reduced. These results clearly indicate that, in addi-
tion to CD4+ T cells, CD8+ T cells are also mediators of this
DTH response. The finding that deletion of CD4+ T cells before
challenge with viable parasites abrogates the development of
this DTH response strongly suggests that CD4+ T cells are
required for CD8+ T cells to mediate a DTH inflammatory reac-
tion in this experimental system. It is noteworthy that upon
challenge with soluble parasite lysates (L.m.Ag), almost no DTH
response was elicited in mice from either group (Fig. 7).
Estimation of the number of parasite-specific CD4+ and CD8+
T cells in lymphoid organs of cured BALB/c mice
The delayed inflammatory reactions (peak at 24 h) mentioned
above assess the presence of Le/s/iman/a-specific CD4+ and
CD8+ T cells by their ability to be activated and mobilized to the
skin site where viable promastigotes are injected and to recruit
CR3+ blood cells (38). This DTH-effector function of both T cell
subsets was used as a read-out system to determine the actual
number of specific cells in lymphoid tissues. The frequencies of
L. ma/cv-specific CD4+ and CD8+ T cells, able to transfer locally
specific DTH responses, were determined in the draining lymph
nodes, the spleens and the blood of either control infected
animals, or BALB/c mice rendered resistant by administration
of a-CD4 mAb 10 days after infection. Serially diluted cell suspen-
sions, depleted or not of either CD4+ or CD8+ T cells, were
mixed with viable L. major promastigotes and injected into the
footpads of normal, syngeneic recipients. After 18 h mice
expressing no increase in footpad thickness (DTH-negative
transfers) were scored. The numbers of L. ma/or-specific T
lymphocytes were calculated from the frequency estimation and
the numbers of nucleated cells in the lymphoid organs. Results
in Fig. 8 confirm and extend previous observations that infec-
Number of L. major reactive T lymphocytes
400 0
Control
aCD4 mAb
day 10/11
100
(1/2x10°) (1/3x10b)
(<1/4x106)
(1/106)
(1/106)
Lymph nodes Spleen
Fig. 8. Number of parasite specific CD4+ and CD8+ T cells in spleens and lymph nodes of infected and of cured BALB/c mice. BALB/c mice
were infected s.c. in one hind footpad with 2 x 106 virulent L. major promastigotes. At days 10 and 11 after infection, one group of BALB/c mice
received 300 jig a-CD4 mAb i.p. After healing of the primary lesion, (day 90) spleen and lymph node cell suspensions were prepared from cured
and control infected BALB/c mice and depleted of either CD4+ or CD8+ T cells by treatment with mAb and complement Serial dilutions of nucleated
cells were transferred along with 2 x 106 viable L. major promastigotes into the footpads of naive syngeneic mice (10-12 mice/dilution). 18 h later,
the negative DTH-transfers were scored and the frequency of specific T cells determined. Thereafter, the numbers of L. major-specific CD4+ and
CD8+ T cells present in lymph nodes and spleens were calculated from the frequency estimation (given in parentheses) and the number of nucleated
cells.
594 CD8+ T cells in L. major infections
Ul
H
CO
-3x10
-2x10
-1x10
m
•o
a
w
m
6
20 60 80 100 120 47 118
days post infection
Fig. 9. Contribution of CD8+ T cells to the reduction of lesion size and parasite burden in susceptible BALB/c mice, rendered resistant by weekly
injections of a-IL-4 mAb. BALB/c mice were infected s.c. in one hind footpad with 2X106 virulent L. major promastigotes. One group of mice
(n = 6 per group) received weekly injections of 500 ng a-IL-4 mAb, starting 2 days before infection. The other group of mice was also treated with
a-IL-4 mAb following the same regimen, and received in addition weekly injections of 150 /»g a-CD8 mAb. Lesion size was determined by subtracting
the footpad thickness of the non-infected footpads from the infected ones. The number of viable parasites present in the lesions were determined
by limiting dilution analysis at days 47 and 118 after infection.
tion of BALB/c mice leads to the expansion of high numbers of
specific CD4+ T cells capable of mediating DTH in response to
viable L. major promastigotes (6). In contrast, compared to control
infected mice, the number of specific CD4+ T cells in draining
lymph nodes of cured BALB/c mice was drastically reduced (Fig.
8). An expansion of specififc CD8+ T cells was observed in the
spleens of cured BALB/c mice (Fig. 8).
Using this test system, it was possible to detect Leishmania-
specific T cells in the blood of mice of both groups. In untreated
blood of infected control mice, we found that 1/3X105
nucleated cells was able to transfer specific DTH responses. After
treatment of blood cells with a-CD4 mAb and complement, the
capacity to transfer specific DTH reaction was abrogated. In
blood of cured BALB/c mice we found that 1/1 x 10s nucleated
cells was able to transfer adoptively specific DTH responses.
Interestingly, while elimination of CD8+ T cells abrogated the
capacity of nucleated blood cells to transfer Leishmania-specff\c
DTH, the removal of CD4+ T cells had no influence on this
effect.
The direct demonstration of the DTH-mediating capacity of
CD8+ T cells using this experimental transfer system possibly
stems from the fact that these cells were injected into normal
recipient mice i.e. with an intact CD4+ T cell compartment.
Contribution of CD8+ T cells in the control of cutaneous
leishmaniasis in BALB/c mice rendered resistant by the
administration of a-IL-4 mAb
Elegant studies by Heinzel et al. (39) have demonstrated that
progression of infection in BALB/c mice is related to the presence
of high amounts of IL-4 mRNA in lymphoid organs. In addition,
a causal role for IL-4 in susceptibility to infection with L. major
has been demonstrated by observations showing that the injec-
tion of specific IL-4 neutralizing mAb rendered BALB/c mice resis-
tant to infection (17). The following experiment was performed
to determine whether or not CD8+ T cells contribute to the
resolution of lesions in those mice. BALB/c mice were infected
s.c. into one hind footpad with 2X108 stationary phase
promastigotes. Mice from the first group were left untreated and
used as controls. Mice from the second group received weekly
injections of 500 HQ a-IL-4 mAb, starting 2 days before infection.
Mice from the third group were treated with mAb following the
same regimen and in addition, received weekly injections of
150 fig a-CD8 mAb, also initiated 2 days before infection. Disease
progression was evaluated by measuring lesion size and deter-
mining the numbers of parasites in lesions. The results in Fig.
9 show, in confirmation with published results (17), that BALB/c
mice administered a-IL-4 mAb are able to control their infection.
Interestingly, the combined treatment of a-IL-4 and a-CD8 mAb
led to the development of more severe lesions. Determination
of parasite numbers at two time points during infection confirm
this contention: mice receiving a-IL-4 and a-CD8 mAbs
harboured —40 times more parasites in their lesions than mice
treated with a-IL-4 mAb only, indicating that the ability to control
infection induced in susceptible mice by treatment with a-IL-4
mAb requires the participation of CD8+ T cells. The effect of
CD8+ T cell depletion in mice treated with a-IL-4 mAb on the
control of infection could only be seen at late times during
infection.
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Discussion
The results presented in this paper strongly suggest that parasite-
specific CD8+ T cells contribute to the host's defense against
infection with the obligate intracellular parasite L. major. The
protective effect of CD8+ T cells has been revealed in suscep-
tible BALB/c mice rendered resistant as a result of two different
interventions on the immune system. First, evidence has been
presented that CD8+ T cells are important for the control of
infection occurring in BALB/c mice as a result of an early treat-
ment with a single dose of a-CD4 mAb. Secondly, the establish-
ment of a state of immunity to reinfection developing in those
mice was shown to be dependent upon an anti-leishmanial
effector function of CD8+ T cells, since the administration of
1OOftg a-CD8 mAb prior to infectious challenge allowed
unrestricted disease progression in these otherwise immune mice
(Fig. 4). Thirdly, CD8+ T cells are also involved in the resolution
of lesions and the reduction of parasite burden which occurs in
susceptible BALB/c mice treated with a-IL-4 mAb. This last obser-
vation is supported by results showing that CD8+ lymphoid cells
from a-IL-4 treated, cured BALB/c mice have the capacity to
transfer adoptively partial protection into 200 R-irradiated
syngeneic recipients (17). The beneficial effect of the administra-
tion of a-IL-4 mAb on the course of cutaneous leishmaniasis in
susceptible BALB/c mice is somewhat surprising, since, in our
hands, no release of IL-4 was detectable upon specific activa-
tion in vitro of freshly isolated spleen and lymph node cells from
infected BALB/c mice, using HT2 cells as detection system (I.
Muller and J. Louis, unpublished observations). However, it is
possible that IL-4-producing cells are concentrated at the site
of infection, where this lymphokine could be neutralized by
specific antibodies.
It has been suggested that CD4+ T cells need to be
permanently eliminated in order for CD8+ T cells to be activated
and to perform a protective function in experimental leishmaniasis
(8). The results presented in this paper clearly indicate that the
beneficial effect of CD8+ T cells on the development of lesions
can occur in susceptible mice with a normal number of CD4 +
T cells in their lymphoid tissues. Indeed, the percentage of
CD4+ T cells in lymphoid organs of a-IL-4 treated mice was
normal, and the proportion of CD4+ T cells in the spleen and
lymph node of mice treated with a single dose of a-CD4 mAb
at the beginning of infection was restored to normal values at
the time when the protective role of CD8+ T cells was evident.
Furthermore, the weekly treatment of mice with a-CD8 mAb did
not adversely affect the numbers of CD4+ T cells as compared
to the controls. Under the two experimental conditions described
here, the protective effect of CD8+ T cells could be detected by
measuring the size of the lesion; however, this protective effect
was much more striking when the number of viable parasites
in the lesions were enumerated (Rgs 3 and 9). Thus, the results
presented here demonstrate again that, since progression of the
lesion size does not necessarily correlate with the number of
parasites in the lesions, the precise quantitation of parasite
numbers in infected tissues represents the more reliable means
to evaluate any protective effect of the immune system on
experimental leishmaniasis (8,40).
Using a very sensitive limiting dilution approach (21), which
allows the detection of a single, specific T cell that is able to
mediate DTH, increased numbers specific CD8+ T cells were
found in lymphoid organs of BALB/c mice rendered resistant to
infection as a result of immunointervention with a-CD4 mAb
(Rg. 8). The presence of specific CD8+ T cells in the Wood of
such mice shows moreover that these cells are able to circulate.
In order to express their anti-Leishmania effector functions, these
specific CD8+ T cells must be mobilized from the recirculating
pool to the infected site where they are specifically activated.
Results obtained suggest that CD4+ T cells are required for
CD8+ T cells to fully express their capacity to mediate DTH
responses, a conclusion currently being investigated in more
detail. It is well documented that the elicitation of DTH responses
depend upon the mobilization of circulating sensitized T cells to
the site of antigenic challenge and their subsequent ability to
recruit CR3+ Wood cells (38). Thus, these results showing that
the administration of a-CD8 mAb prior to antigenic challenge with
viaWe L. major promastigotes significantly impairs parasite-
specific DTH responses strongly suggest that specific CD8+ T
cells are recruited to the site of lesion where they restrict parasite
growth.
The expansion of parasite-specific CD8+ T cells in these mice
indicates that parasite antigens are presented in the context of
MHC class I molecules. In this respect it is of interest that in all
the experiments described in this report, the optimal stimulation
of effector functions of CD8+ T cells (DTH and lymphokine
production) was dependent upon the use of living promastigotes
as a source of antigen. Thus, it seems that some antigens of this
intracellular microorganism, which lives exclusively in the
phagosome-lysosome compartment, may, after processing,
somehow associate with class I MHC products of their host cells.
A hypothetical leak of some parasite products from those vesicles
to the cytosol would make parasite antigens availaWe for the MHC
class I pathway of presentation (42). It is also possiWe that
peptides from Leishmania parasites are released from infected
cells and are able to Wnd to MHC class I molecules expressed
on the surface of neighboring uninfected cells. However, our
observations that CD8+ T cells are required for the elimination
of parasites in infected tissues suggest that CD8+ T cells
recognize antigens expressed at the surface of parasitized
macrophages. It is worth mentioning that in a variety of infec-
tions with intracellular microorganisms, such as mycobacteria and
Listeria, the development of protective immunity also depends
upon the triggering of CD8+ T cells, and that vaccination with
viaWe microorganisms confers optimal protection (41,42).
Several mechanisms could account for the protective effect
of CD8+ T cells in experimental cutaneous leishmaniasis.
Activation of parasitized macrophages by T cell-derived lympho-
kines is considered to be the essential mechanism by which
parasites are destroyed in infected tissues. Thus, it is possiWe
that the protective function of CD8+ T cells is expressed through
production of macrophage-activating cytokines. Results in Fig. 5
indicate that the release of IFN-7, IL-2 and TNF by specifically-
activated spleen cells from BALB/c mice, cured as a result of
treatment with a-CD4 mAb at the initiation of infection, was
drastically reduced after depletion of CD8+ T cells in vivo.
These results clearly indicate that CD8+ T cells participate in the
production of cytokines which have been ascribed anti-leish-
manial effector functions (16,43-45). A direct cytotoxic effect
of CD8+ T cells on parasitized macrophages cannot, however,
be excluded.
A final point which merits emphasis is the fact that significant
amounts of IFN-7 were measured in supernatants of specifically-
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activated lymphoid cells from infected, susceptible BALB/c mice
(Fig. 5 and manuscript in preparation). Inasmuch as release of
IFN-7 is significantly higher upon stimulation of lymphoid cells
from infected BALB/c mice with living parasites, it would be of
interest to determine the phenotype of the T cells from these mice
capable of releasing these lymphokines. Thus, our results further
indicate that the susceptibility of BALB/c mice to infection with
L. major cannot simply be ascribed to an inability to produce
IFN-7.
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